Ashland(ASH) ZACKS·2025-05-01 00:35Core Insights - Ashland reported revenue of $479 million for the quarter ended March 2025, a decrease of 16.7% year-over-year, and EPS of $0.99, down from $1.27 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $508.82 million by 5.86%, and the EPS was also below the consensus estimate of $1.10 by 10% [1] Revenue Performance - Life Sciences revenue was $172 million, below the estimated $177.02 million, reflecting a year-over-year decline of 22.5% [4] - Intermediates revenue reached $37 million, slightly above the estimated $36.38 million, but still down 7.5% from the previous year [4] - Specialty Additives revenue was $134 million, compared to the average estimate of $141.10 million, marking a 14.7% decrease year-over-year [4] - Personal Care revenue was $146 million, below the estimated $162.83 million, representing a year-over-year decline of 13.6% [4] Adjusted EBITDA Performance - Adjusted EBITDA for Life Sciences was $56 million, exceeding the estimate of $53.75 million [4] - Adjusted EBITDA for Intermediates was $2 million, significantly below the estimate of $6.15 million [4] - Adjusted EBITDA for Specialty Additives was $26 million, slightly above the estimate of $25.22 million [4] - Adjusted EBITDA for Personal Care was $44 million, below the average estimate of $46.25 million [4] Stock Performance - Ashland's shares have returned -7.4% over the past month, compared to a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]